Replimune Soars 17% as TUDRIQEV Melanoma Launch Draws “Enthusiastic” Response From Physicians
Replimune (REPL) shares rose 17% after reporting strong initial uptake of TUDRIQEV, its melanoma treatment, with over 15 institutions prescribing it in three weeks. The company has $307.8 million in cash. TUDRIQEV is used with Bristol Myers Squibb's (BMY) Opdivo and targets tumors not treated by Amgen's (AMGN) Imlygic. Analysts expect revenue growth, but no sales figures are available yet.
How this was made
The 30-second read
Why it matters
The 17% share surge reflects market enthusiasm for the new therapy, but future performance hinges on sales data and continued cash runway.
Market read
The article provides fresh, material information on a biotech launch that moved the stock sharply, offering a clear trading opportunity.
What to watch
Potential competition from Amgen's Imlygic and the need for continued cash to fund the launch.
Background
Replimune's TUDRIQEV is an oncolytic virus therapy for melanoma, administered with Bristol Myers' Opdivo.
Ticker impact
Replimune shares jumped 17% after the first three weeks of its TUDRIQEV melanoma launch saw prescriptions at over 15 institutions.
likely upward pressure as investors price in accelerating sales and potential revenue growth.
First‑hand uptake data and a double‑digit intraday move indicate fresh catalyst; however, sales figures are still pending.
Market effects
Oncolytic virus therapies may see heightened investor interest, benefiting the biotech sector.
U.S. biotech market receives a boost from the launch news.
Limited to companies developing similar tumor‑injection therapies.
Counterpoint
The launch may face higher-than-expected costs and regulatory hurdles, tempering upside.
Key entities
- CompanyReplimune Group
Developer of TUDRIQEV, subject of the article.


